Yes. A food ingredient can legally be sold in the United States without ever receiving FDA premarket approval if its intended use qualifies as “Generally Recognized as Safe,” or GRAS.
The reason is surprisingly technical but important: under federal law, a substance whose use is legitimately GRAS is excluded from the legal definition of a “food additive.” Because the FDA’s ordinary premarket approval requirement applies to food additives, a GRAS use does not have to go through that approval process. Congress deliberately created this exception in the 1958 Food Additives Amendment; it was not simply an exemption invented later by the FDA or food companies.
That does not mean a manufacturer can simply declare, “We think this is safe,” and legally put anything into food. GRAS has its own safety standard, evidentiary requirements, and legal consequences if the determination is wrong. But there is a genuine oversight issue at the center of the system: under the rules in effect as of August 14, 2026, a company can independently conclude that a use is GRAS without first obtaining FDA approval—and without being required to tell the FDA about that determination. FDA proposed changing the notification requirement on August 11, 2026, but that proposal is not yet final.
Understanding that distinction explains both why the GRAS system exists and why it has become controversial.
GRAS does not mean “FDA-approved”
The easiest mistake is treating safe, GRAS, and FDA-approved as interchangeable terms.
They are not.
For an ordinary food additive, a manufacturer generally must establish safety to the FDA and obtain authorization for the proposed conditions of use before marketing it. For GRAS, the legal theory is different: qualified experts already generally recognize the safety of the substance for those particular conditions of use, so a separate food-additive approval is unnecessary.
The current system can be simplified this way:
| Regulatory pathway | Who initially establishes the basis for safety? | FDA review before marketing required? | What does FDA issue? |
|---|---|---|---|
| Food additive | Sponsor submits evidence; FDA makes the regulatory determination | Yes | Authorization through a food-additive regulation |
| GRAS with voluntary FDA notice | Manufacturer or other proponent concludes the use is GRAS | No | FDA may issue a “no questions,” “insufficient basis,” or other response |
| Independent or “self-GRAS” determination | Manufacturer or other proponent concludes the use is GRAS | No | Nothing, unless FDA later becomes involved |
This distinction is why the phrase “FDA-approved ingredient” can be misleading when discussing food. Some ingredients are approved food additives. Others are lawfully used because their particular use falls outside the food-additive approval requirement.
And even when FDA reviews a voluntary GRAS notice and sends a “no questions” letter, the agency says that letter is not an FDA affirmation that the ingredient is GRAS. The company remains responsible for the conclusion. FDA’s newly proposed regulations would make this distinction even more explicit.
What does “Generally Recognized as Safe” actually mean?
GRAS is not supposed to mean merely that a company believes an ingredient is probably harmless.
FDA regulations define safety as a reasonable certainty among competent scientists that a substance is not harmful under its intended conditions of use. Absolute proof of harmlessness is not required—FDA explicitly recognizes that science cannot establish absolute zero risk—but the evaluation must consider probable consumption, cumulative dietary exposure to the substance and related substances, and appropriate safety factors.
For newer ingredients relying on scientific evidence, GRAS has an additional requirement that is easy to overlook: the quantity and quality of scientific evidence required to establish safety are supposed to be the same as those required for approval of a food additive.
The difference, therefore, is not supposed to be:
Food additive = scientifically proven safe
versus
GRAS = somebody assumes it is safe.
The more accurate distinction is:
Food additive = FDA makes the premarket regulatory decision.
GRAS = the proponent determines that the safety of the specific use is already generally recognized among qualified experts and therefore does not require food-additive approval.
GRAS actually contains two elements. The scientific evidence must establish safety, and that safety must also be generally recognized within the relevant expert scientific community. FDA has said that scientific GRAS conclusions ordinarily depend on generally available information, often published scientific literature, rather than safety evidence known only to the manufacturer.
A handful of scientists privately seeing favorable studies is therefore not necessarily enough.
GRAS applies to a use—not simply to an ingredient
This is another major source of confusion.
An ingredient is not necessarily “GRAS” for every imaginable purpose, concentration, manufacturing process, or population. What matters legally is the substance under its intended conditions of use.
A substance might be GRAS at one concentration in certain foods but require a different safety analysis at a much higher exposure. A change in manufacturing could introduce different impurities. A use that dramatically increases total dietary exposure could also alter the analysis. FDA regulations specifically recognize that significantly different conditions of use may require a new GRAS basis or food-additive authorization.
That is why saying simply that “Ingredient X is GRAS” can be incomplete. The more precise statement is that a particular use of Ingredient X is GRAS under specified conditions.
How does “self-affirmed GRAS” work?
The phrase “self-affirmed GRAS” or “self-GRAS” is commonly used for what FDA documents also describe as an independent conclusion of GRAS status.
In practice, a manufacturer develops a scientific record supporting the proposed use. That normally involves defining the substance and manufacturing process, determining how much consumers are likely to encounter, reviewing toxicology and other relevant research, considering cumulative exposure, and deciding whether qualified scientists would generally recognize the intended use as safe.
Some companies convene an independent group of scientists commonly called a GRAS panel, but that is not legally required. FDA says that, in many cases, a well-supported GRAS determination does not require a panel at all. A panel is simply one possible way of demonstrating that the conclusion reflects the views of the broader qualified scientific community.
The important legal point is that the company remains responsible.
A manufacturer cannot make an unsafe substance legally GRAS merely by writing “GRAS” in a file or paying experts to sign a report. FDA’s 2016 rule makes clear that a legitimate GRAS conclusion must satisfy both the safety requirement and the general-recognition requirement. A genuine dispute among qualified experts over whether the proposed use is safe can prevent the required general recognition from existing, and the evaluation should take account of unfavorable as well as favorable evidence.
So “self-GRAS” means the company can make the initial regulatory determination itself. It does not mean the company gets to invent the legal standard itself.
What must a manufacturer actually establish?
For a scientifically based GRAS determination, the company needs substantially more than a favorable toxicology study.
It must be able to identify what the substance actually is, including characteristics relevant to its safety and manufacturing. It needs defined conditions of use—what foods it will be added to, why it is being used, at what levels and resulting exposures. The safety analysis must consider the probable amount people will consume, relevant cumulative exposure, related substances in the diet and appropriate safety factors.
The evidence must support a reasonable certainty that the substance will not be harmful under those conditions. For scientific GRAS determinations, the evidence supporting safety must meet the same quantity-and-quality standard applicable to food additives, while the basis for general recognition must be generally available and accepted within the relevant scientific community.
There is also an older route for substances with a substantial history of food consumption before January 1, 1958. In those cases, general recognition can be based on experience from common use rather than the same modern scientific-evidence pathway.
That historical route helps explain why familiar ingredients such as vinegar, oils and ordinary spices do not need individual modern FDA approvals simply because they are intentionally added to food. FDA itself uses ingredients such as canola oil, vinegar and black pepper as examples when explaining GRAS to consumers.
Why would Congress create a system like this?
Because requiring a full FDA food-additive petition for every familiar or scientifically uncontroversial ingredient would make little regulatory sense.
When Congress enacted the Food Additives Amendment in 1958, it created a broad requirement for premarket review of food additives but simultaneously recognized that many substances did not need that process because their safety was already established through common food use or broadly available scientific knowledge.
That original principle is not particularly radical.
Requiring FDA to formally approve vinegar, common spices or an established food oil every time a company wanted to use one would consume regulatory resources without necessarily increasing public safety.
The harder question is what happens when the same legal category is used for a newer, technically complex ingredient whose GRAS conclusion was developed by the company that wants to sell it.
That is where the modern debate begins.
So what is controversial about self-GRAS?
The strongest criticism is not that GRAS contains no safety requirements. It clearly does.
The concern is who performs the evaluation, what the FDA knows about it, and whether there is enough independent oversight.
Under the current system, a company may independently determine that an ingredient’s intended use is GRAS and market it without submitting that conclusion to the FDA. The Government Accountability Office highlighted this problem as far back as 2010, noting that companies could make GRAS determinations without FDA approval or even FDA knowledge and recommending greater agency visibility into those decisions.
That creates a straightforward information problem. FDA cannot systematically scrutinize a determination it does not know exists.
There is also an inherent potential conflict of interest when the company that benefits financially from selling an ingredient is responsible for establishing the scientific basis for avoiding premarket approval.
A 2013 study in JAMA Internal Medicine examined 451 GRAS notices submitted between 1997 and 2012. It found that the safety evaluations were performed by manufacturer employees, consultants selected by manufacturers, or expert panels selected by manufacturers or their consultants. The authors argued that these relationships created widespread conflict-of-interest concerns. The study does not establish that those ingredients were unsafe or that their scientific conclusions were necessarily wrong; it demonstrates why the independence of the decision-making process became a legitimate oversight issue.
FDA subsequently issued final guidance in 2022 recommending safeguards when companies use GRAS panels, including balanced expertise and procedures for identifying and managing conflicts of interest and the appearance of bias.
That is meaningful oversight guidance—but it is guidance, not a replacement for FDA itself making every premarket decision.
Is self-GRAS really a “loophole”?
Yes and no, depending on what the word means.
Calling the entire GRAS exemption a loophole is historically misleading. Congress expressly created the GRAS exclusion in 1958 because it did not want every commonly used or generally recognized safe substance to undergo formal food-additive approval. That part is intentional statutory design.
When critics refer to the “GRAS loophole,” they are usually criticizing something narrower: the ability of a company to reach an independent GRAS conclusion and market the substance without first telling FDA.
That is a real feature of the present regulatory structure, not an invented criticism. GAO raised essentially the same oversight concern in 2010, and FDA’s own 2026 proposed rule says an unknown number of substances may have entered the market under the GRAS provision without the agency having complete visibility into them.
The most accurate description, therefore, is that GRAS itself is a deliberate exemption; mandatory disclosure of independent GRAS determinations is the oversight gap now being reconsidered.
A “no questions” letter is not the same as FDA approval
There is an intermediate category that often creates confusion.
Companies can currently submit GRAS notices voluntarily. FDA reviews the basis for the conclusion and may respond that it has “no questions at this time” regarding the notifier’s GRAS conclusion.
That sounds very similar to approval, but legally it is not.
FDA says a typical no-questions letter makes clear that the notifier remains responsible for the GRAS conclusion, that FDA’s response reflects the information available at that particular time, and that the response is not an FDA affirmation of GRAS status.
This distinction matters when marketing materials say something like “FDA GRAS approved.” Depending on the underlying regulatory history, that wording may overstate what FDA actually did.
GRAS status can change when the science changes
GRAS is not necessarily permanent.
FDA regulations expressly state that new information can require reconsideration of an ingredient’s GRAS status.
Partially hydrogenated oils provide a major real-world example. They were once widely treated as GRAS, but after evidence concerning artificial trans fats accumulated, FDA issued a final determination in 2015 that partially hydrogenated oils were no longer GRAS for use in human food.
That history demonstrates two things simultaneously.
The GRAS system is not legally incapable of correcting previous safety assumptions. But it also demonstrates why post-market reassessment matters: scientific understanding, consumption levels and the food supply itself can change long after an ingredient first enters widespread use.
FDA is now changing how post-market reviews work
A second major reform is already underway outside the GRAS-notification debate.
On May 12, 2026, FDA announced that it had finalized a systematic process for post-market assessment of chemicals in food. The framework includes identifying and triaging safety signals, prioritizing substances for review, conducting scientific assessments and deciding what risk-management action is appropriate. FDA simultaneously announced reassessments involving butylated hydroxytoluene (BHT) and azodicarbonamide (ADA).
That does not eliminate the premarket transparency issue surrounding independent GRAS determinations, but it addresses a related weakness: an ingredient that once appeared safe needs a mechanism for reconsideration when exposure patterns or scientific evidence change.
The biggest GRAS reform may be happening right now
On August 11, 2026, just three days before this article was updated, FDA formally proposed converting its voluntary GRAS notification system into a largely mandatory notification system. The public comment period is scheduled to run through December 9, 2026.
If finalized substantially as proposed, companies introducing substances under the GRAS provision would generally have to notify FDA of the basis for their GRAS conclusion, subject to specified exceptions. The proposal also includes a time-limited streamlined process intended to bring information about existing independently determined GRAS uses into a public record.
But there is a crucial distinction:
FDA is not proposing to turn GRAS into ordinary premarket approval.
The proposed rule expressly says companies could still introduce a substance into commerce after reaching a GRAS conclusion before submitting the notice or before FDA completes its review. The mandatory notice would primarily increase transparency and give FDA the information needed for oversight and post-market intervention rather than making FDA the initial decision-maker for every GRAS use.
That difference will likely get lost in headlines describing the government as “ending self-GRAS.”
The proposed system would substantially reduce the ability to keep an independent GRAS determination entirely outside FDA’s view. It would not, as currently written, create a universal rule that every purported GRAS ingredient must receive FDA permission before being sold.
And because this is a proposed rule, those provisions could change before any final regulation takes effect.
Congress has considered going further
FDA rulemaking is not the only reform proposal.
During the 119th Congress, lawmakers introduced multiple bills aimed at changing GRAS oversight. The Grocery Reform And Safety Act (H.R. 4958) proposed notification to FDA before GRAS use, reassessment of certain substances and additional resources for FDA reviews. The Ensuring Safe and Toxic-Free Foods Act of 2025 (S. 2341) proposed broader GRAS requirements, recurring reassessment of food substances and strengthened standards concerning experts involved in GRAS evaluations.
Neither proposal should be confused with current law. They illustrate the range of reforms under debate—from simply making GRAS determinations visible to FDA to substantially expanding independent review and recurring safety reassessment.
Does this mean ingredients that were never FDA-approved are unsafe?
No.
“Not FDA-approved” describes a regulatory pathway. It is not, by itself, a toxicological conclusion.
Some of the most ordinary ingredients in the American food supply are lawfully used without having gone through a modern food-additive approval process. FDA specifically cites substances such as vinegar and common spices when explaining GRAS.
It would therefore be misleading to take the statement “FDA never approved this ingredient” and automatically translate it into “the ingredient was never evaluated for safety.”
But the opposite claim would also be misleading.
A GRAS determination does not necessarily mean FDA independently reviewed the evidence before consumers were exposed to the ingredient. Under the present system, FDA may have reviewed a voluntary notice, may have previously listed or affirmed a substance as GRAS, or may have had no premarket involvement at all.
When evaluating claims about a particular ingredient, the better questions are:
What specific use is claimed to be GRAS? What evidence supports that conclusion? Was the evidence generally available? Who conducted the evaluation? Was a GRAS notice submitted? Did FDA respond? Have exposure levels changed? Has newer scientific evidence emerged?
Those questions tell consumers far more than the words “FDA-approved” or “not FDA-approved” alone.
Can any company simply declare an ingredient GRAS?
No. A company can make an independent GRAS conclusion, but that does not automatically make the conclusion legally correct.
The use must actually satisfy federal GRAS criteria. If it does not—and no other exception from the food-additive definition applies—the substance is an unapproved food additive. FDA can then take enforcement action against the ingredient or foods containing it.
The distinction is similar to many other areas of regulatory law: a business may initially be responsible for determining that it complies with the law, but the government’s failure to preapprove the decision does not immunize the company if its conclusion proves wrong.
Does GRAS mean an ingredient is “natural”?
No.
GRAS is a safety and regulatory classification, not a statement about whether an ingredient is natural, synthetic, minimally processed or artificial. The relevant question is whether qualified experts generally recognize the substance as safe under its intended conditions of use.
Does GRAS mean an ingredient is safe at any amount?
No.
The conditions of use—including exposure and concentration—are fundamental to the determination. FDA’s safety definition specifically requires consideration of probable consumption and cumulative dietary exposure. A use that is GRAS at one exposure level does not automatically establish that dramatically larger exposures would also be GRAS.
Can FDA later decide that a GRAS ingredient is unsafe?
Yes.
New information can trigger reconsideration, and FDA can conclude that a use does not satisfy GRAS requirements. Its determination that partially hydrogenated oils were no longer GRAS is the clearest modern example.
The bottom line
A food ingredient can legally be sold without FDA approval because Congress created GRAS as an alternative regulatory pathway for uses whose safety is already generally recognized among qualified experts.
The scientific standard is more substantial than the phrase “self-affirmed” sometimes suggests. For scientific GRAS determinations, FDA regulations require the same quantity and quality of safety evidence required for a food additive, along with generally available evidence sufficient to produce general recognition within the relevant scientific community.
But the controversy surrounding the system is also legitimate.
Under the rules in effect on August 14, 2026, companies can independently make GRAS determinations without mandatory FDA notification. That means the regulator may not know every substance or use being marketed under the exemption, and the party with a financial interest in commercialization can play a major role in determining whether the exemption applies.
FDA’s newly proposed mandatory-notification rule would close much of that information gap if finalized—but it would not eliminate manufacturer GRAS determinations or turn GRAS into conventional FDA premarket approval.
That is the nuance missing from both extremes of the debate.
“The FDA never approved it” does not mean “nobody had to establish that it was safe.”
But “it is GRAS” does not necessarily mean “FDA independently determined it was safe before it entered the food supply.”
Both statements can be true at the same time.
References and Further Reading
Primary law, regulations and regulatory history
FDA — Generally Recognized as Safe (GRAS) — FDA’s main overview of the GRAS framework, including the distinction between food additives and GRAS uses and the scientific-evidence standard.
Electronic Code of Federal Regulations — 21 CFR § 170.30: Eligibility for Classification as Generally Recognized as Safe (GRAS) — The core federal regulation establishing the scientific and common-use routes to GRAS status and requiring scientific GRAS evidence to match the quantity and quality required for food-additive approval.
Electronic Code of Federal Regulations — 21 CFR § 170.3: Definitions — Defines “safe,” “scientific procedures,” common use in food, cumulative dietary exposure and other concepts central to GRAS determinations.
Federal Register — Substances Generally Recognized as Safe, Final Rule (2016) — FDA’s detailed history and interpretation of the 1958 GRAS exemption and the rule that established the modern voluntary notification procedure. Particularly useful for understanding why GRAS exists and how general recognition differs from a simple private safety opinion.
Current GRAS procedures and scientific review
FDA — Guidance for Industry: Best Practices for Convening a GRAS Panel — Explains that GRAS panels are not mandatory and provides FDA recommendations concerning appropriate expertise, independence, bias and conflicts of interest when panels are used.
FDA — Understanding How the FDA Regulates Food Additives and GRAS Ingredients — Consumer-oriented FDA explanation of the difference between food additives and GRAS ingredients, with familiar examples and an explanation of manufacturers’ legal responsibilities.
Oversight and conflict-of-interest research
U.S. Government Accountability Office — Food Safety: FDA Should Strengthen Its Oversight of Food Ingredients Determined to Be Generally Recognized as Safe (GRAS) — Major 2010 government review documenting FDA’s limited visibility into independent GRAS determinations and recommending stronger oversight.
JAMA Internal Medicine — Conflicts of Interest in Approvals of Additives to Food Determined to Be Generally Recognized as Safe: Out of Balance — Peer-reviewed 2013 study examining financial relationships among individuals and panels responsible for hundreds of voluntarily submitted GRAS determinations. Useful as evidence of the structural conflict-of-interest debate, not as evidence that every examined ingredient was unsafe.
Post-market safety and changing scientific evidence
FDA — Final Determination Regarding Partially Hydrogenated Oils (Removing Trans Fat) — Important real-world example of FDA determining that previously accepted uses were no longer GRAS after the scientific evidence changed.
FDA — Understanding the FDA’s Systematic Process for Ensuring the Post-Market Safety of Chemicals in Food — Describes FDA’s current systematic framework for identifying, prioritizing, assessing and managing safety questions involving chemicals already present in the food supply.
FDA — FDA Finalizes Food Chemical Safety Post-Market Assessment Program, Launches Reassessment of BHT, ADA — May 12, 2026 announcement documenting implementation of the new post-market assessment program.
Current and proposed reforms
Federal Register — Substances Generally Recognized as Safe, Proposed Rule (August 11, 2026) — The most important current source on GRAS reform. FDA proposes converting voluntary notification into a generally mandatory notification system while expressly stopping short of creating ordinary premarket approval for GRAS substances. Comments are scheduled to close December 9, 2026.
Congress.gov — H.R. 4958, Grocery Reform And Safety Act (GRAS Act) — Congressional proposal addressing prior notification, reassessment and FDA resources for GRAS oversight.
Congress.gov — S. 2341, Ensuring Safe and Toxic-Free Foods Act of 2025 — Senate proposal addressing GRAS determinations, recurring reassessment of food chemicals and standards for experts involved in GRAS evaluations.
Editorial note
Regulatory status verified August 14, 2026. The FDA rule published August 11, 2026 is a proposed rule, not current final law, and its requirements may change through the notice-and-comment process. Articles discussing GRAS rules before August 2026 may therefore describe the reform effort differently or omit the newly proposed mandatory-notification framework altogether.
